SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is experiencing intense debate and price volatility following reports of a California court ruling challenging its "Full Self-Driving" branding, raising questions about the company's autonomous technology claims. This fuels widespread discussion, with bears pointing to market overvaluation and FSD limitations, while many bulls remain confident in a rebound to recent highs. The strong contrasting perspectives highlight ongoing investor focus on Tesla's future technology and broader market movements.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is heavily discussed as its earnings report looms, with the community sharply divided between strong bullish expectations driven by soaring AI-related memory demand and fears of a post-earnings sell-off mirroring recent reactions in the broader semiconductor sector. Many believe robust demand and rising memory prices will lead to a strong report, but sector-wide profit-taking after strong earnings remains a key concern.

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.

Processa Pharmaceuticals Inc

Processa Pharmaceuticals is actively trending after announcing positive preliminary Phase 2 data for its NGC-Cap treatment in metastatic breast cancer, demonstrating increased drug efficacy without additional side effects. This crucial update, combined with the company's low share float following a recent reverse split, has fueled intense trading volume and multiple circuit breaker halts. The community is buzzing with bullish sentiment, anticipating substantial price appreciation, though some express caution regarding the stock's volatility and historical patterns.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group (GRRR) is trending following multiple analyst upgrades, notably a "strong-buy" rating from Cantor Fitzgerald with a significant price target, signaling growing confidence in its future. Additionally, an ongoing lawsuit against alleged market manipulators is drawing community attention as a fight to stabilize the stock's valuation. Investors are actively debating the company's substantial contract pipeline and projected revenue growth against concerns over past stock performance and alleged manipulation, with many highlighting GRRR's perceived undervaluation and low float amidst broader AI sector volatility.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is experiencing extreme volatility amid speculation surrounding GE Vernova's entry into the fuel cell space and broader market sentiment shifts regarding AI-driven data center spending. The community is sharply divided, with some attributing the sharp price drops to institutional manipulation and tax-loss harvesting, while others see these dips as prime buying opportunities given the company's strong long-term fundamentals in clean energy infrastructure.

Medline, Inc. engages in the provision of medical-surgical products and supply chain solutions. It operates through the Medline Brand and Supply Chain Solutions segments. The Medline Brand segment is involved in the procurement and manufacture of products from surgical solutions, front line care, and laboratory and diagnostics categories. The Supply Chain Solutions segment focuses on procurement and distribution of a variety of third-party products from national brands and provides tailored logistics and supply chain optimization services to domestic and international consumers. The company was founded by Jim Mills and Jon Mills in 1966 and is headquartered in Northfield, IL.

Medline Inc - Ordinary Shares - Class A

Medline Inc.

Medline Inc. ($MDLN) is trending due to its recent, highly anticipated IPO, which was heralded as one of the largest of the year and saw its stock debut with a significant price jump. The community is actively discussing their initial share allocations and the company's future trajectory, balancing its strong position as a medical supply giant and stable cash flows against its notable debt load. Sentiment is mixed, with some holding for long-term growth and others anticipating a potential pullback after the initial market excitement.

Hut 8 Corp. operates as a Bitcoin miner that focuses on mining. It provides digital asset mining, hosting, and managed infrastructure operation services. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is trending following its announcement of a new AI infrastructure partnership with Anthropic and Fluidstack, which includes a substantial data center lease agreement with reported backing from Google. The community is buzzing about this strategic pivot, seeing it as a transformative move from primarily Bitcoin mining into the high-demand AI sector and a catalyst for diversified revenue streams. Many anticipate a significant re-evaluation of the company's future potential.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending amidst excitement over a new joint development agreement with a major global automaker, the operational readiness of its 'Eagle Line' manufacturing facility, and its upcoming move to the Nasdaq exchange. Community discussion centers on eagerly anticipated OEM reveals and the company's path to commercialization. While many view these milestones as significant derisking steps, some investors are openly frustrated by the lack of named partners and immediate stock performance despite the positive announcements.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending due to conflicting reports surrounding a significant data center financing deal, with initial news suggesting a key partner withdrew funding while Oracle maintains the project is on schedule with a new backer. This uncertainty fuels intense community debate over the company's substantial debt and ambitious AI infrastructure plans. The situation is seen by some as a potential "AI bubble" indicator, contributing to broader tech sector weakness.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is experiencing significant market attention driven by expectations of an imminent executive order to reclassify cannabis to Schedule III. Community discussions are highly polarized, anticipating a major short squeeze and substantial upward movement, while others caution about the direct benefits for Canadian-based operators versus US multi-state cannabis companies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -26.24% and -71.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates

Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of +84.62% and +4.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?

Armata Pharmaceuticals (ARMP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

<ul class="summary-bullets"><li>The company’s bacteriophage therapy AP-SA02 achieved an 88% response rate in a Phase 2a trial for Staphylococcus aureus bacteremia, with no relapses reported.</li><li>H.C. Wainwright reiterated a ‘Buy’ rating and $9 target, saying the results support advancing AP-SA02 into Phase 3 next year.</li><li>Retail traders flooded Stocktwits with bullish posts after the record rally, with some predicting further gains while others expected a share offering.</li></ul>Shares of Armata Pharmaceuticals surged to a record high on Wednesday after the company reported encouraging Phase 2a results for its experimental bacteriophage therapy, AP-SA02, in patients with complicated Staphylococcus aureus bacteremia (SAB), a serious and often life-threatening bloodstream infection.The stock logged its best session on record on Wednesday, surging 103% to close at $7.05, and fell 16% in after-hours trading as investors took profits following the steep rally.Promising Results In Early-Stage TrialThe findings show for the first time, in a randomized trial, that intravenous phage therapy can be efficacious for S. aureus bacteremia.&nbsp;The diSArm study showed that patients treated with AP-SA02 in addition to the best available antibiotic therapy had an 88% clinical response rate at day 12, compared with 58% for placebo. No patients treated with AP-SA02 relapsed or were non-responsive, versus approximately 25% of patients who received&nbsp;a placebo.A total of 42 patients were enrolled in the trial, and about 38% of the cases had infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Armata said that the treatment was well-tolerated with no serious adverse events associated with the drug.The company is looking to move AP-SA02 into a Phase 3 trial in 2026, based on these results, subject to regulatory input from the U.S. Food and Drug Administration.Analyst ViewH.C. Wainwright reaffirmed its ‘Buy’ rating and $9 price target on Armata, representing a 28% upside from the company’s last close. The brokerage said the results, along with supporting in vitro data, provide “strong evidence for the efficacy of its core therapeutic strategy.” The firm said the data support moving the bacteriophage therapy into a pivotal late-stage study next year.Multi-Phage Cocktail Shows Broad Efficacy&nbsp;Armata said AP-SA02, a fixed cocktail of multiple bacteriophages, showed consistent efficacy against both MRSA and methicillin-sensitive S. aureus (MSSA) and was linked to faster infection clearance and shorter hospital stays. The company received $26.2 million in funding from the U.S. Department of Defense through the Medical Technology Enterprise Consortium to support the diSArm study.Stocktwits Traders See Potential Stock Offering&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 26,200% surge in 24-hour message volume.One user said they expected the company to announce a share offering following the surge in its stock price.<stembedurl>https://stocktwits.com/FredDurst/message/633328173</stembedurl>Another user, however, struck an optimistic tone, predicting that the stock could double in value the next day.<stembedurl>https://stocktwits.com/Lifeinlight/message/633324622</stembedurl><a href="https://stocktwits.com/symbol/ARMP">Armata’s stock</a> has&nbsp;rocketed 281% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Armata Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Armata Pharmaceuticals Stock Soars To Record High After Phage Therapy Data In Deadly Infection Trial; Retail Traders Pile In

H.C. Wainwright reiterated a ‘Buy’ rating and $9 target, saying the results support advancing AP-SA02 into Phase 3 next year.

Equity

Are Medical Stocks Lagging  Armata Pharmaceuticals (ARMP) This Year?

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?

Here is how Arbutus Biopharma (ABUS) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.

All You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy

Armata Pharmaceuticals (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

Armata Pharmaceuticals Inc

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

ARMP
Armata Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARMP News

ARMPArmata Pharmaceuticals Inc